Arca
Skip to content
Tools
Tools

MAPK11: Mitogen-activated protein kinase 11

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 2

Who Is On It, and How Far Along

Every drug ChEMBL records acting on MAPK11, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Regorafenib

Phase 31

  • Losmapimod

Phase 20

    Phase 11

    • RWJ-67657

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: MAP kinase p38 beta inhibitor.
    RegorafenibApprovedBayerSmall moleculeInhibitor—96Boxed warning
    LosmapimodPhase 3GSKSmall moleculeInhibitor—0—
    RWJ-67657Phase 1—Small moleculeInhibitor—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsRegorafenibPhase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.2026-10-05
    Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerRegorafenibPhase 2Not yet recruitingFujian Cancer Hospital2026-08-14
    A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerRegorafenibPhase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.2026-08-06
    A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanRegorafenibPhase 3Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.2026-07-28
    IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRegorafenibPhase 3RecruitingInnovent Biologics (Suzhou) Co. Ltd.2026-07-23
    Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat SyndromeRegorafenibPhase 2Not yet recruitingXiang-Qian2026-07-09
    A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibRegorafenibPhase 2RecruitingGlaxoSmithKline2026-07-08
    Clinical Study of Novel Therapeutic Vaccine for Advanced Solid TumorsRegorafenibPhase 1RecruitingWest China Hospital2026-05-05

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Neoplasm
    0.39
    Colorectal neoplasm
    0.37
    Colon carcinoma
    0.26
    Malignant colon neoplasm
    0.26

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3961, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q15759, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.